Key result
Central-acting and alpha-1 adrenoreceptor blocking agents are reserved as fifth-line antihypertensives for resistant hypertension due to poorer tolerance and lack of cardiovascular outcome trials.
Why the study?
Central antihypertensives and alpha-blockers are often used more frequently in practice than recommended by guidelines.
Central-acting and alpha-1 blocking agents are reserved as fifth-line antihypertensives for resistant hypertension due to their side effect profile and lack of large mortality trials, though they offer benefits in specific comorbidities.
Reinforces fifth-line reservation of central-acting and alpha-1 blockers in resistant hypertension; leaves open dedicated outcome trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Iva Prokopová (2019) conducted a review in Resistant hypertension. Central-acting and alpha-1 adrenoreceptor blocking antihypertensives was evaluated. Central-acting and alpha-1 adrenoreceptor blocking agents are reserved as fifth-line antihypertensives for resistant hypertension due to poorer tolerance and lack of cardiovascular outcome trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: